Close Menu

reagents

Finnzymes had $20 million in revenues in 2009 and makes reagents, consumables, kits, and instruments for molecular biology applications.

The company will make and sell a Manchester-developed diagnostic reagent technology through an agreement that includes a research collaboration.

While revenues fell short of analysts' expectations for the quarter, the legacy Invitrogen business reported 7 percent organic revenue growth. The Q4 revenue numbers also do not include mass spec sales, which are now accounted for as an equity investment. In addition, company officials predicted 2009 organic revenue growth in the low single-digits.

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.